NSE
BSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Krsnaa Diagnostics drives top-line growth and network expansion, though rising costs and debt pressure weigh on near-term profits.
Revenue from operations grows from ₹1,930 Cr in Q1 FY26 to ₹2,355 Cr in Q1 FY27, confirming robust market expansion.
Finance costs rise from ₹63 Cr in Q1 FY26 to ₹148 Cr in Q1 FY27, indicating rising debt servicing pressure.
EBITDA climbs from ₹514 Cr in Q1 FY26 to ₹580 Cr in Q1 FY27, showing resilient core profitability.
Revenue share in the East slips from 13% in Q1 FY26 to 10% in Q1 FY27, signaling weakening regional demand.
Touch points expand from 3,479 in Q1 FY26 to 8,400 in Q1 FY27, reflecting aggressive customer acquisition.
Total expenses surge from ₹1,406 Cr in Q1 FY26 to ₹1,767 Cr in Q1 FY27, reflecting aggressive capacity scaling.
Satellite labs jump from 114 in Q3 FY26 to 175 in Q1 FY27, signaling rapid last-mile expansion.
Depreciation charges jump from ₹216 Cr in Q1 FY26 to ₹280 Cr in Q1 FY27, reflecting heavy asset additions.
Fees to hospitals and others spike from ₹143 Cr in Q4 FY26 to ₹406 Cr in Q1 FY27, highlighting major B2B contract wins.
PAT moderates from ₹205 Cr in Q1 FY26 to ₹166 Cr in Q1 FY27, showing profit volatility amid expansion costs.
